Senetek

Frank J. Massino, Chairman of the Board and Chief Executive Officer of Senetek, said, "We have been impressed by our review to date of IGI's proprietary delivery technologies and new product pipeline. Our review has confirmed a number of synergies potentially achievable by the combination of the two companies' technologies, customer bases and product development initiatives. We very much look forward to completing our review and working with the IGI team to complete this transaction."

This press release does not constitute an offer of any stock or other securities of Senetek, IGI or any other party for sale.

Senetek is a life sciences-driven product development and licensing company focused on the high growth market for products primarily addressing age-related conditions. Senetek's patented compound Kinetin is a naturally occurring cytokinin that has proven effective in improving the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients. Senetek has licensed Kinetin to leading global and regional dermatological and skin care marketers including Valeant Pharmaceuticals, The Body Shop and Revlon, and has licensed its Invicorp erectile dysfunction technology to Ardana Bioscience Ltd. for Europe, with rights to additional markets. Senetek's researchers at the University of Aarhus, Denmark, also are collaborating with the Institute of Experimental Botany, Prague, and with Beiersdorf AG, Hamburg, to identify and evaluate additional new biologically active compounds for the high growth skin care field.

IGI is a company committed to growth by applying its proprietary technologies to achieve cost-effective solutions with differential consumer advantages for its customers. IGI's patented Novasome(R) micro-encapsulation technology offers value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption controlled and sustained release as well as improved stability and greater ease of formulation. IGI has licensed Novasome technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Corporation, Genesis Pharmaceutical, Inc. and Apollo Pharmaceutical, Inc., and recently sub-licensed Tarpan Therapeutics, Inc. to obtain FDA approval for and market IGI's PTH 1-34 compound using Novasome technology for psoriasis.

Senetek PLC Investor Relations Contact: 1-707-226-3900 ext. 102 E-mail: Pknopick@eandecommunications.com Safe Harbor Statement

This news release contains statements that may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act, including those that might imply the parties' expectation of the successful completion of the transactions contemplated by the letter of intent and success in combining the two companies and realizing hoped for synergies. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the companies that they believe could result in such material differences are described in their respective Annual Reports on Form 10-K for the year 2003 and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. However, the companies necessarily can give no assurance that they have identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and neither assumes any obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Senetek PLC

Web site: http://www.senetekplc.com/

Copyright © 2004 PRNewswire
News Copyright © 2004 Interest!ALERT All rights reserved.

     
       

       
     

für senetek - es soll doch nicht etwa doch noch was werden ?
hier der Text:
Senetek PLC erhält mindestens 37 Mio. USD über fünf Jahre für erweiterte Rechte an Kinetin und eine ausschliessliche Zeatin-Lizenz



NAPA, Kalifornien, August 9 /PRNewswire/ -- Senetek PLC (OTC Bulletin Board: SNTKY), www.senetekplc.com, eine Pharma-Technologiefirma, die sich auf die Entwicklung und Massenvermarktung von Produkten für die wachsenden weltweiten Anti-Aging-Märkte konzentriert, gab heute die Unterzeichnung einer neuen Vereinbarung mit ihrem Marketing-Partner, Valeant Pharmaceuticals International (NYSE: VRX), bekannt. Valeant erhält erweiterte Vertriebsrechte für Kinetin, das die Firma zurzeit unter der Marke Kinerase(R) vertreibt und ausschliessliche weltweite Herstellungs- und Marketing-Rechte für Zeatin. Im Gegenzug dafür erhält Senetek PLC vor vorhandenen Gutschriften ein garantiertes Minimum an Lizenzgebühren in Höhe von 6 Mio. USD im Jahr 2006, 7 Mio. USD im Jahr 2007 und jeweils 8 Mio. USD in den Jahren 2008, 2009 und 2010 mit der Möglichkeit weiterer Lizenzgebühren.

gruss E8

oder hat schon mal einer die Produkte getestet ?
gruss E8

gruss e8

das krokodil wird hungrig

Senetek PLC Revenue Increases 44% In 2006
--Reports Positive Net Income and Cash Flow From Operations--
Napa, CA April 9, 2007 Senetek PLC (OTCBB:SNTKY), www.senetekplc.com, a life sciences product development company targeting the science of aging, announced results for the fourth quarter and year ended December 31, 2006.

Financial Highlights

Revenue for the year ended December 31, 2006 increased 44% to $8,431,000, compared with $5,871,000 reported in 2005. Revenues for the fourth quarter of 2006 increased 41% to $2,130,000, compared with $1,511,000 for the same period in the prior year. The increase is principally attributed to increased royalties from Valeant Pharmaceuticals International stemming from the July 2005 amendment to the Kinetin and Zeatin license agreement.

Net income for the year ended December 31, 2006 totaled $1,883,000 or $0.03 per share compared to a net loss of $1,739,00, or $0.03 per share in 2005. Net income for the year ended December 31, 2006 included a $927,000 non-cash expense for the write-off of the debt discount on retirement of the Senior Secured Notes in March and a $250,000 gain on the sale of Reliaject® assets in March. Net income for the fourth quarter of 2006 was $575,000, or $0.01 per share compared with a loss of $801,000, or $0.01 per share in the fourth quarter of 2005.

Cash flow from operations for the year ended December 31, 2006 increased to $1,290,000 compared with $(1,406,000) used in 2005 operations.

"Senetek delivered another solid quarter," said Frank J. Massino, Senetek's Chairman and CEO. "We believe our performance in 2006 coupled with the recently announced agreement with Valeant has laid the economic foundation to rapidly accelerate development of our rich pipeline of proprietary compounds, to acquire products, and to achieve our corporate goal of commercializing one new compound each year."

Mr. Massino continued, "Senetek's new focus will place increased emphasis on direct marketing efforts of new products with our sights on achieving greater revenues and larger economic benefits. This new strategic direction will also redirect our product development efforts to target unmet needs in the lucrative and growing prescription dermatological therapeutic market."

On April 2, 2007, Senetek granted a paid up license for Kinetin and Zeatin and assignment to Valeant of future royalties from other Kinetin licensees, in return for a cash payment of $21 million, forgiveness of a $6 million prepaid royalty credit reimbursement obligation that Senetek otherwise would have owed to Valeant, and a right to share in future royalties due to Valeant from other Kinetin licensees through 2011.

The Company will conduct its quarterly teleconference call for investors on Tuesday, April 24 at 9:00 a.m. Pacific, 12:00 p.m. Eastern. Mr. Frank J. Massino, Chairman & CEO and Mr. William F. O'Kelly, Chief Financial Officer, will discuss the third quarter operating results and the outlook for the remainder of 2006. The domestic dial-in number is 800-894-5910; the international dial-in number is 785-424-1052, conference ID: SENETEK. Replay of the conference call will be available until Tuesday, May 1. Domestic Replay dial-in 800-839-5123, International Replay dial-in 402-220-2689, replay conference ID: SENETEK.



About Senetek:
Senetek PLC (OTCBB: SNTKY) is a life sciences product development company with a portfolio of intellectual properties targeting the science of aging, including skincare and dermatological therapeutics, erectile dysfunction and nutrition. Kinetin, Senetek's lead commercial product, is currently licensed and marketed by 14 pharmaceutical and cosmeceutical companies, and Senetek has entered into an exclusive global license with Valeant Pharmaceuticals for Senetek's proprietary anti-aging skincare compound Zeatin. In addition, Senetek has entered into exclusive licenses for Europe and North America, respectively, for its patented combination drug treatment for erectile dysfunction, Invicorp®, has an exclusive manufacturing distributorship for its proprietary diagnostic monoclonal antibodies, and recently sold, with retained rights of profit participation, its patented drug delivery system, Reliaject®.


For additional information, please visit Senetek PLC’s web site at:
www.senetekplc.com





Company Contact:

Senetek PLC:

Phone: 1-707-226-3900, ext. 102  Investor Contact:

The Investor Relations Group
Jordan Silverstein/Christine Berni or Lyn Granito, Public Relations
Phone 212-825-3210  

Safe Harbor Statement:
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act, including those indicating the financial outlook for fiscal 2007 and those that might imply commercial potential and successful evaluation and development of new compounds. Forward- looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward- looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Handelsplätze Name Kurs Veränderung Datum Umsatz

Berlin 0,01 -95,65% 09:14 06.08. 0

Frankfurt 0,201 +0,00% 09:13 06.08. 3.200

NASDAQ OTC Bulletin Board 0,29 +0,00% 20:12 03.08. 100